CAT3, a novel agent for medulloblastoma and glioblastoma treatment, inhibits tumor growth by disrupting the Hedgehog signaling pathway
- 1 October 2016
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 381 (2) , 391-403
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science of China (81202433, 21132009)
- National Major Scientific and Technological Special project for “Significant New Drugs Development” during the Twelfth Five-year Plan Period (2012ZX09301002-006)
This publication has 50 references indexed in Scilit:
- The dawn of hedgehog inhibitors: VismodegibJournal of Pharmacology and Pharmacotherapeutics, 2013
- Synthesis, Biological Evaluation and Mechanism Studies of Deoxytylophorinine and Its Derivatives as Potential Anticancer AgentsPLOS ONE, 2012
- Blocking Hedgehog Survival Signaling at the Level of the GLI Genes Induces DNA Damage and Extensive Cell Death in Human Colon Carcinoma CellsCancer Research, 2011
- Hedgehog Signaling Drives Cellular Survival in Human Colon Carcinoma CellsCancer Research, 2011
- Inhibition of the Hedgehog Pathway in Advanced Basal-Cell CarcinomaNew England Journal of Medicine, 2009
- Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449New England Journal of Medicine, 2009
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityJournal of Computational Chemistry, 2009
- Patched1 Regulates Hedgehog Signaling at the Primary CiliumScience, 2007
- Natural Products as Sources of New Drugs over the Last 25 YearsJournal of Natural Products, 2007
- GLI transcription factors: Mediators of oncogenic Hedgehog signallingEuropean Journal of Cancer, 2006